Stoke Therapeutics is a biopharmaceutical company developing RNA-based medicines to treat severe genetic diseases caused by loss of protein function, using its proprietary TANGO platform of antisense oligonucleotides designed to restore protein expression in patients with haploinsufficiency conditions. The company's lead program targets Dravet syndrome, a severe genetic epilepsy affecting thousands of patients with no disease-modifying treatments, while a secondary program addresses autosomal dominant optic atrophy, and the pipeline targets additional rare CNS and eye diseases. Stoke generates revenue through potential commercial sales of its drug candidates in North America and through milestone payments and royalties from a partnership with Biogen covering international territories.